P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Targeting Bcl-2 for the treatment of multiple myeloma.
TL;DR: The present review summarizes the current knowledge, “from bench to bedside”, about venetoclax for the treatment of multiple myeloma.
Journal ArticleDOI
Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel
Bruce D. Cheson,Clemens-Martin Wendtner,Angelika Pieper,Martin Dreyling,Jonathan W. Friedberg,Dieter Hoelzer,Philippe Moreau,John G. Gribben,Stefan Knop,Marco Montillo,Mathias J. Rummel +10 more
TL;DR: A consensus meeting was convened to develop recommendations for standardizing the administration of Bendamustine based on the available clinical data, and recommendations were developed including dose and schedule for the various clinical indications, as a single agent and in combination therapy.
Journal ArticleDOI
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
Christopher R. McCudden,Amy Axel,Dominique Slaets,Thomas Dejoie,Pamela L. Clemens,Sandy Frans,Jaime Bald,Torben Plesner,Joannes F M Jacobs,Niels W.C.J. van de Donk,Philippe Moreau,Jordan M. Schecter,Tahamtan Ahmadi,A. Kate Sasser +13 more
TL;DR: As the treatment of myeloma evolves to incorporate novel monoclonal antibodies, additional solutions will be needed for clinical monitoring of patient responses to therapeutic regimens and assays such as DIRA can inform clinical outcomes by distinguishing daratumumab from endogenous M-protein by IFE.
Journal ArticleDOI
Cefepime/Amikacin Versus Ceftazidime/Amikacin as Empirical Therapy for Febrile Episodes in Neutropenic Patients: A Comparative Study
Catherine Cordonnier,Raoul Herbrecht,Jose Luis Pico,Martine Gardembas,Alain Delmer,Martine Delain,Philippe Moreau,Saloua Ladeb,Véronique Nalet,Christian Rollin +9 more
TL;DR: It is concluded that the combination cefepime/amikacin is at least as effective as the reference regimen of ceftazidime/AMIKacin in this setting.
Journal ArticleDOI
Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.
Philippe Moreau,Noel-Jean Milpied,Béatrice Mahé,Nadine Juge-Morineau,M. J. Rapp,Régis Bataille,J-L Harousseau +6 more
TL;DR: The data suggest thatHDM220 followed by ASCT should be considered in patients with primary refractory disease or chemosensitive disease relapsing after prior intensive therapy, and low β2-microglobulin and CRP levels at the time of HDM220 were associated with a better OS and EFS.